» Articles » PMID: 20887095

Surgical Outcomes for Older Patients with Glioblastoma Multiforme: Preoperative Factors Associated with Decreased Survival. Clinical Article

Overview
Journal J Neurosurg
Specialty Neurosurgery
Date 2010 Oct 5
PMID 20887095
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

Object: As the population ages, the incidence of glioblastoma multiforme (GBM) among older patients (age > 65 years) will increase. Older patients, unlike their younger counterparts, are not often offered aggressive surgery because of their age, comorbidities, and potential inability to tolerate surgery. The goal of this study was to identify preoperative factors associated with decreased survival for older patients who underwent resection of a GBM. The identification of these factors may provide insight into which patients would benefit most from aggressive surgery.

Methods: All patients older than 65 years who underwent nonbiopsy resection of an intracranial GBM at a single institution between 1997 and 2007 were retrospectively reviewed. Factors associated with overall survival were assessed using multivariate proportional hazards regression analysis after controlling for peri- and postoperative factors known to be associated with outcome (extent of resection, carmustine wafer implantation, temozolomide chemotherapy, and radiation therapy). Variables with p < 0.05 were considered statistically significant.

Results: A total of 129 patients with an average age of 73 ± 5 years met the inclusion/exclusion criteria. At last follow-up, all 129 patients had died, with a median survival of 7.9 months. The preoperative factors that were independently associated with decreased survival were Karnofsky Performance Scale (KPS) score less than 80 (p = 0.001), chronic obstructive pulmonary disease (p = 0.01), motor deficit (p = 0.01), language deficit (p = 0.005), cognitive deficit (p = 0.02), and tumor size larger than 4 cm (p = 0.002). Patients with 0-1 (Group 1), 2-3 (Group 2), and 4-6 (Group 3) of these factors had statistically different survival times, where the median survival was 9.2, 5.5, and 4.4 months, respectively. In log-rank analysis, the median survival for Group 1 was significantly longer than that for Group 2 (p = 0.004) and Group 3 (p < 0.0001), while Group 2 had longer survival than Group 3 (p = 0.02).

Conclusions: Older patients with an increasing number of these factors may not benefit as much from aggressive surgery as patients with fewer factors. This may provide insight into identifying which patients older than 65 years of age may benefit from aggressive surgery.

Citing Articles

Prediction of Survival in the Elderly Patients with Glioblastoma using Cumulative Inflammatory Markers Score.

Song K, Chen C, Xu H, Chen L, Xu H, Han X J Neurol Surg B Skull Base. 2025; 86(1):98-105.

PMID: 39881741 PMC: 11774615. DOI: 10.1055/s-0044-1779050.


Differences in tumor size, clinical, demographic, and socioeconomic profiles of central nervous system tumors among a racially diverse cohort: A retrospective case-control study.

Kim K, Lew R, Higashihara T, Yamashita S, Pang M, Stafford M Surg Neurol Int. 2025; 15():459.

PMID: 39777174 PMC: 11704430. DOI: 10.25259/SNI_190_2024.


Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomide.

Zeyen T, Bohm L, Paech D, Schafer N, Tzaridis T, Duffy C Neuro Oncol. 2024; 27(2):557-566.

PMID: 39351820 PMC: 11812022. DOI: 10.1093/neuonc/noae205.


The global immune-nutrition-inflammation index (GINI) as a robust prognostic factor in glioblastoma patients treated with the standard stupp protocol.

Topkan E, Durankus N, Senyurek S, Ozturk D, Besen A, Mertsoylu H Int J Immunopathol Pharmacol. 2024; 38:3946320241284089.

PMID: 39305006 PMC: 11440555. DOI: 10.1177/03946320241284089.


Resection versus biopsy in patients with glioblastoma (RESBIOP study): study protocol for an international multicentre prospective cohort study (ENCRAM 2202).

Gerritsen J, Young J, Krieg S, Jungk C, Ille S, Schucht P BMJ Open. 2024; 14(9):e081689.

PMID: 39260848 PMC: 11409263. DOI: 10.1136/bmjopen-2023-081689.


References
1.
Brandes A, Compostella A, Blatt V, Tosoni A . Glioblastoma in the elderly: current and future trends. Crit Rev Oncol Hematol. 2006; 60(3):256-66. DOI: 10.1016/j.critrevonc.2006.06.014. View

2.
Kreth F, Faist M, Rossner R, Volk B, Ostertag C . Supratentorial World Health Organization Grade 2 astrocytomas and oligoastrocytomas. A new pattern of prognostic factors. Cancer. 1997; 79(2):370-9. DOI: 10.1002/(sici)1097-0142(19970115)79:2<370::aid-cncr21>3.0.co;2-x. View

3.
McGirt M, Chaichana K, Gathinji M, Attenello F, Than K, Olivi A . Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2008; 110(1):156-62. DOI: 10.3171/2008.4.17536. View

4.
McGirt M, Mukherjee D, Chaichana K, Than K, Weingart J, Quinones-Hinojosa A . Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery. 2009; 65(3):463-9. DOI: 10.1227/01.NEU.0000349763.42238.E9. View

5.
Hutterer M . Elderly patients with glioblastoma multiforme--an underestimated subpopulation?. Neuroepidemiology. 2009; 33(1):23-4. DOI: 10.1159/000210018. View